Literature DB >> 1394333

Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.

H Inoue1, M Adachi, N Karimine, S Arinaga, H Ueo, D Korenaga, T Akiyoshi.   

Abstract

The intensity of lymphoid cell infiltration and distribution of lymphocyte subsets in tumors were investigated immunohistochemically on tumor tissues obtained from 11 patients with gastric carcinoma, who had been treated with mitomycin C (MMC), 12 mg/m2, i.v. 5 days before operation. The results were compared with those obtained from 24 untreated patients as controls. In the tumor tissues from pretreated patients, the intensity of lymphoid infiltration was not significantly different from that of untreated patients. However, high-grade infiltration of CD4+ cells was observed in 55% of pretreated patients, whereas only 8% of control patients exhibited the high-grade infiltration (P < 0.02). Since the CD8+ cell infiltration was not significantly altered, the ratio of CD4+ to CD8+ cells was more frequently estimated to be more than 1 in patients pretreated with MMC, as compared to untreated controls (P < 0.02). Further, CD25+ cells in pretreated tumor tissues were more predominant than those in control tumor tissues (P < 0.05). These results suggest that MMC administration induces these alterations in lymphocyte subsets in tumor tissue in patients with gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394333     DOI: 10.1007/bf01741141

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer.

Authors:  R Bilik; C Mor; B Hazaz; C Moroz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest.

Authors:  R Lafreniere; K Borkenhagen; L D Bryant; E Ng
Journal:  J Biol Response Mod       Date:  1989-06

3.  Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients.

Authors:  S Arinaga; T Akiyoshi; H Tsuji
Journal:  Int J Immunopharmacol       Date:  1988

4.  Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma.

Authors:  J H Finke; R Tubbs; B Connelly; E Pontes; J Montie
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

Authors:  C M Balch; L B Riley; Y J Bae; M A Salmeron; C D Platsoucas; A von Eschenbach; K Itoh
Journal:  Arch Surg       Date:  1990-02

6.  In vitro tumor cell killing by peritoneal macrophages from mitomycin C-treated rats.

Authors:  T Ogura; H Shindo; O Shinzato; M Namba; T Masuno; T Inoue; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.

Authors:  B Y Takesue; J M Pyle; M B Mokyr
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

8.  Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2.

Authors:  S Takagi; K Chen; R Schwarz; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

9.  Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.

Authors:  M Nagarkatti; S R Clary; P S Nagarkatti
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

10.  Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors:  H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.